HopeStage
Back to all studies
CompletedNCT00544544

Riluzole for treatment-resistant bipolarity depression

About this title

Riluzole in the Treatment of Bipolar Depression

Read the official source — NCT00544544

Researchers studied Riluzole to find out how it affected depression symptoms in people with bipolarity during a depressive episode.

Medication studyAges 18–65United States
The study in practice

Understand this study

What did researchers investigate?

Researchers studied Riluzole to find out how it affected depression symptoms in people with bipolarity during a depressive episode.

Who was this study for?

This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
BelmontSee all locations and recruitment

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJune 2007
Recruitment status
Completed
Enrollment listed in the registry
14
Sponsor
Mclean Hospital
Sponsor type
Hospital / academic medical center
Study type
Drug
Intervention type
Drug
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT00544544
Official title
Show the full official title

Riluzole in the Treatment of Bipolar Depression: A Study of the Association Between Clinical Response and Change in Brain Glutamate Levels as Measured by Proton Magnetic Resonance Spectroscopy

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Belmont

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

Researchers studied Riluzole to find out how it affected depression symptoms in people with bipolarity during a depressive episode.

Who is behind this study?

The study sponsor is Mclean Hospital, a hospital or academic medical center.

Did this study involve medication?

Yes. The study involved medication, including Riluzole.

Who was this study for?

This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies